Recovery of ovarian function and pregnancy in a patient with AML after myeloablative busulphan-based conditioning regimen

J Pediatr Hematol Oncol. 2011 May;33(4):e154-5. doi: 10.1097/MPH.0b013e3181faf7b5.

Abstract

We report a rare case of ovarian function recovery and pregnancy after hormone-replacement therapy (HRT) in the acute myeloblastic leukemia (AML) patient in third complete remission received hematopoietic stem cell transplantation (HSCT) with busulphan-based conditioning regimen. Successful engraftment of the donor cells and full donor's chimerism was achieved without the signs of leukemia. One year after HSCT the patient received a course of HRT as a treatment of hypergonadotropic hypogonadism. After 12 months of HRT the recovery of ovarian function was confirmed. Eight years after the HSCT spontaneous pregnancy occurred; heartbeat of the fetus was registered on week 7. Three weeks later a nonsevere vaginal bleeding occurred and the ultrasound examination showed a nondeveloping pregnancy. Genetic examination of the abortion material showed a full triploid genotype (69 XXX). To our knowledge this is a first case of ovarian function restoration and spontaneous pregnancy in a AML patient after multiple courses of high-dose chemotherapy and busulphan-based myeloablative conditioning for HSCT.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Busulfan / administration & dosage*
  • Busulfan / adverse effects
  • Child
  • Combined Modality Therapy
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Hypogonadism / drug therapy
  • Leukemia, Myeloid, Acute / drug therapy*
  • Myeloablative Agonists / administration & dosage
  • Myeloablative Agonists / adverse effects
  • Ovary / physiology*
  • Pregnancy
  • Pregnancy Outcome
  • Recovery of Function*
  • Transplantation Conditioning / adverse effects
  • Transplantation Conditioning / methods*
  • Young Adult

Substances

  • Antineoplastic Agents
  • Myeloablative Agonists
  • Busulfan